Innovative designs of CAR-T cells to enhance their efficacy and function were described, including CAR-T cells with co-expression of a fusion protein between extracellular domain of PD-1 and transmembrane/signaling domain of CD28 to rescue them from hypofunction and enhance their tumor-killing effects [79]. Here, PDCD1 is linked to neoplasm.